《公司业绩》国药控股(01099.HK)全年纯利71.9亿人币升14.9% 派末期息0.69元人币
国药控股(01099.HK)公布截至去年12月底止全年业绩,营业额4,564.15亿元人民币(下同),按年升7.3%。纯利71.87亿元,按年升14.9%;每股盈利2.31元。派末期息0.69元,上年同期派0.6元。
去年度集团医药分销板块收入占比下降4个百分点至74.18%,而医疗器械和药品零售板块则分别上升2.98个百分点和0.56个百分点,达到19.04%和5.15%。截至去年底,公司累计开展集中配送和SPD项目总计达1,735个,较上一年度增加790个。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.